Related Experiment Videos

Low Concentration Intra-Tympanic Gentamicin Treatment for Menière's Disease: A Long-Term Follow Up

Shlamkovitch Nathan1, Reut Lasry, Eviatar Ephraim

  • 1Department of Otolaryngology Head and Neck Surgery, Assaf Harofeh Medical Center, Zerifin, Israel.

Abstract

Insights

Low-concentration intra-tympanic gentamicin injections effectively treat Meniere's disease (MD) vertigo. Long-term hearing levels in treated ears showed no significant difference compared to untreated ears, addressing safety concerns.

Area of Science:

  • Otolaryngology
  • Neurosurgery
  • Pharmacology

Background:

  • Intra-tympanic gentamicin injections (ITG) are used for Meniere's disease (MD) unresponsive to conservative therapy.
  • ITG's ototoxic nature raises safety concerns regarding hearing preservation.

Purpose of the Study:

  • To evaluate the effect of low-concentration ITG on ipsilateral hearing compared to the contralateral ear in refractory MD.
  • To assess the effectiveness of low-concentration ITG treatment for Meniere's disease.

Main Methods:

  • A retrospective cohort study (2003-2015) compared hearing changes in injected vs. untreated contralateral ears.
  • Audiometric data was analyzed to assess short-term and long-term hearing threshold differences.

Main Results:

  • Treatment success was observed in 74.1% of patients after one ITG course.
  • Short-term hearing showed improvement at 1000 Hz and deterioration at 8000 Hz compared to the control ear.
  • Long-term analysis, adjusted for confounders, revealed no significant hearing level difference between treated and untreated ears.

Conclusions:

  • Low-concentration ITG demonstrates high success rates in managing vertigo for refractory unilateral MD.
  • This treatment approach appears safe concerning long-term hearing thresholds when compared to the contralateral ear.

Related Concept Videos